The $63 Billion Bet That Broke Everything
On June 7, 2018, Bayer AG closed the largest all-cash acquisition in corporate history: $63 billion for Monsanto, the St. Louis agrochemical giant that had become, depending on whom you asked, either the most important agricultural company on Earth or the most hated corporation in America. Werner Baumann, Bayer's CEO at the time, had fought for two years to consummate the deal — surviving regulatory gauntlets in 30 jurisdictions, divesting €7.6 billion in assets to satisfy antitrust demands, and loading the company's balance sheet with roughly €35 billion in debt. The strategic logic was seductive: combine Bayer's crop protection chemicals with Monsanto's seed genetics and digital farming platform to create an unrivaled life sciences colossus. "Health for all, hunger for none" — Bayer's corporate mission — would no longer be aspirational but structural.
Three days after the deal closed, Bayer's name was removed from the Monsanto brand. But the liability could not be so easily erased. Within months, Dewayne Johnson, a California school groundskeeper dying of non-Hodgkin's lymphoma, won a $289 million jury verdict against Monsanto for its glyphosate-based herbicide Roundup — a product Bayer had just spent the better part of its market capitalization to acquire. By 2020, the company faced roughly 125,000 Roundup-related lawsuits and agreed to pay more than $10 billion in settlements, with future claims still unresolved. Bayer's share price, which had hovered near €100 before the Monsanto announcement in 2016, would crater to around €20 by late 2023 — a destruction of roughly €80 billion in equity value, more than the purchase price of the acquisition itself.
The Monsanto deal is the gravitational center of modern Bayer — the strategic wager from which all subsequent crises radiate. But the deeper story is older and stranger than any single transaction. Bayer is a company that has died and been resurrected at least twice, that invented both aspirin and heroin, that was absorbed into one of history's most notorious corporate entities and then clawed its way back to independence, that has oscillated between transformative scientific breakthroughs and catastrophic institutional failures for more than 160 years. It is a company whose very name — stamped onto white tablets in medicine cabinets across every continent — carries a weight of trust that its corporate decisions have periodically betrayed. The tension between Bayer the brand and Bayer the institution is the oldest story in its archive, and the one its newest CEO is trying, with radical organizational surgery, to resolve.
By the Numbers
Bayer AG at a Glance
€46.6BFY 2024 sales
€10.1BEBITDA (2024, -13.5% YoY)
~94,000Employees worldwide
€6.2BR&D investment in 2024
~€20BApproximate market cap (late 2024)
€34.5BNet debt
80+Countries with operations
161Years since founding
Two Kitchen Stoves in Wuppertal
The chemical industry emerged in mid-nineteenth-century Germany the way Silicon Valley would emerge in mid-twentieth-century California — through the convergence of scientific knowledge, entrepreneurial hunger, and a transformative shift in what the economy demanded. In the Wupper Valley, the textile mills needed dyes. Natural pigments — indigo from India, cochineal from Mexico — were scarce and expensive. The synthesis of aniline dyes from coal tar, first achieved in England in 1856, opened a new frontier. Into that frontier stepped two men with complementary skills: Friedrich Bayer, a dye salesman born in 1825, the son of a silkworker, who by twenty was dealing in natural pigments and by twenty-three had built a distribution network stretching from London to St. Petersburg; and Johann Friedrich Weskott, a master dyer five years his senior, who understood the craft from the production side. They experimented with fuchsine synthesis on two kitchen stoves in Barmen. On August 1, 1863, they entered "Friedr. Bayer et comp." into the commercial register.
What distinguished Bayer from the dozens of other dye factories founded in those years was a willingness to invest in research when the returns were uncertain. By 1881, when the partnership converted to a joint stock company — "Farbenfabriken vorm. Friedr. Bayer & Co." — the workforce had grown from 3 to more than 300. Friedrich Bayer himself was already dead, gone at 54 in 1880, but the institutional logic he and Weskott established would outlast them both: hire scientists, give them resources, commercialize what they find, and sell it internationally. By 1913, over 80 percent of Bayer's revenues came from exports. Of the company's 10,000 employees, nearly 1,000 worked outside Germany.
The architect of Bayer's scientific ambition was Carl Duisberg, a chemist who joined in 1884 and would become the dominant figure in the company's pre-war history. Duisberg built a research laboratory in Wuppertal-Elberfeld that set new standards in industrial R&D — not a professor's curiosity cabinet but a systematic capability for turning chemical knowledge into commercial products. Under his direction, the company's research efforts yielded a stream of intermediates, dyes, and, increasingly, pharmaceuticals. It was in Duisberg's laboratory that the molecule would emerge that would define the company's identity for the next century and beyond.
The Drug of the Century
In 1897, Felix Hoffmann, a Bayer chemist working in the Elberfeld pharmaceutical department, succeeded in synthesizing a chemically pure and stable form of acetylsalicylic acid. The compound itself was not new — salicin, the active precursor, had been derived from willow bark since Hippocrates — but previous formulations were unstable and notoriously hard on the stomach. Hoffmann's achievement was not discovery but refinement: making the molecule usable at industrial scale. Bayer patented the drug on March 6, 1899, and registered the trademark Aspirin.
The product's commercial impact was immediate and enduring. Aspirin became the world's most widely used medication — a universal remedy for pain, fever, and inflammation that would later reveal unexpected properties in cardiovascular prevention and cancer research. It traveled to the Moon aboard Apollo 11 in 1969, packed in the onboard pharmacy alongside other carefully selected medications. But Aspirin's significance for Bayer was not merely pharmaceutical. It proved that a chemical company could build a branded consumer product of global ubiquity — that research conducted in a German laboratory could generate trust in households on every continent. The Bayer Cross, registered on January 6, 1904, became inseparable from the tablet.
Brand and molecule fused into a single commercial identity.
There was also heroin. In 1898, a year before Aspirin's launch, Bayer began marketing diacetylmorphine as a cough suppressant and pain remedy, including to children. The company sold it commercially under the brand name Heroin — derived from the German heroisch, meaning heroic, for the way it made patients feel. The drug was promoted as non-addictive. It was, of course, profoundly addictive. Bayer eventually discontinued heroin production, but the episode foreshadowed a recurring pattern: the company's scientific capabilities would periodically outrun its institutional capacity for caution.
We cannot be like Google, but neither do we want to be. We need to plot our own path.
Absorbed Into Darkness
World War I severed Bayer from its export markets. The company lost access to the foreign revenues that had driven its growth, and in the United States — its most important single market — Bayer's assets, patents, and even the Aspirin trademark were seized as enemy property under the Trading with the Enemy Act of 1917. The brand that Friedrich Bayer had spent decades building abroad was stripped away in months.
The postwar economy made it clear that individual German chemical companies could not reclaim their former positions alone. In 1925, six firms — Bayer, BASF, Hoechst, Agfa, and two smaller companies — merged to form Interessengemeinschaft Farbenindustrie AG, known as I.G. Farben. Bayer transferred its assets to the new entity. Its entry as an independent company in the commercial register was deleted. It ceased to exist as a legal person.
What followed is the darkest chapter in the history of any extant corporation. I.G. Farben became Germany's largest industrial enterprise and, under the Nazi regime, one of its most important instruments. The conglomerate produced synthetic fuels, rubber, and explosives critical to the war effort. Its subsidiary Degesch manufactured Zyklon B, the cyanide-based pesticide used in the gas chambers of Auschwitz. At the Lower Rhine operating consortium — which included Bayer's former Leverkusen, Dormagen, Elberfeld, and Uerdingen sites — forced laborers from occupied Europe were deployed to maintain and expand production capacities. At times, these forced laborers accounted for up to a third of the workforce. Around 16,000 people were deployed at the Lower Rhine sites during the war, thousands of them — predominantly from Poland, Ukraine, and other Eastern European countries — forced to work under inhumane conditions. The youngest were 14 years old.
In 1947, 23 senior I.G. Farben managers stood trial at Nuremberg. Thirteen received custodial sentences. All were eventually granted early release. Fritz ter Meer, sentenced to seven years for "plunder and spoliation" and "mass murder and enslavement," produced a document known as the "Kransberg Memorandum" before his trial that made no mention of forced laborers' suffering and painted I.G. Farben's leaders as patriotic victims of the Nazi regime. After his release, ter Meer became Chairman of the Supervisory Board of the reestablished Farbenfabriken Bayer AG, serving from 1956 to 1964. The refusal of institutional accountability was total.
⚖️
I.G. Farben and Its Legacy
The corporate entity that consumed Bayer for two decades
1925Six German chemical companies merge to form I.G. Farbenindustrie AG. Bayer ceases to exist as an independent entity.
1936Nazi government begins systematic war preparations; I.G. Farben's sites deemed vital to war economy.
1940Forced laborers from occupied Europe deployed at Lower Rhine sites; up to one-third of workforce at peak.
1945Allied Forces seize I.G. Farben; all sites placed under Allied officer control.
194723 I.G. Farben senior managers tried at Nuremberg; 13 convicted.
1951Bayer reestablished as Farbenfabriken Bayer AG on December 19.
2023Bayer establishes Hans and Berthold Finkelstein Foundation to sharpen culture of remembrance and support research on forced labor at I.G. Farben.
Bayer's present-day posture toward this history is unusual among German corporations. Rather than minimizing the connection, the company has leaned into it — building a memorial to forced labor victims next to its Leverkusen headquarters, establishing the Hans and Berthold Finkelstein Foundation in April 2023 to support independent research on I.G. Farben's role during the Nazi era. But the moral weight is unresolvable. A company that exists because it was reconstituted from the wreckage of an enterprise complicit in industrialized genocide does not get to declare the ledger balanced. The history is structural, embedded in the institutional DNA — a permanent asterisk next to every humanitarian claim.
The Second Life
The founding meeting of the reestablished Farbenfabriken Bayer AG took place on December 19, 1951. For the second time in its history, the company had lost its foreign assets, its patents, its international sales organization — everything it had built abroad. The reconstruction was inseparable from the Wirtschaftswunder, the German economic miracle that transformed the Federal Republic from rubble into the world's third-largest economy in barely a decade.
Ulrich Haberland, the first Chairman of the Board of Management after the war, led the rebuilding. Bayer began reestablishing its foreign sales activities as early as 1946, while still under Allied control. The push into international markets accelerated through the 1950s and 1960s under Kurt Hansen, who served as Management Board Chairman from 1961 to 1974 and oversaw the company's transformation from a German chemical manufacturer into a genuinely global operation. New production sites were established. The workforce expanded. The product portfolio diversified — chemicals, polymers, pharmaceuticals, crop protection, diagnostics.
The oil crisis of 1973 ended the miracle. When Herbert Grünewald succeeded Hansen in 1974, chemical raw material prices had quadrupled within months. Grünewald responded with consolidation and a pioneering focus on ecological and social responsibility that was unusual for an industrial company of that era. His successor, Hermann Josef Strenger (1984–1992), strengthened divisional and financial structures. Manfred Schneider (1992–2002) achieved a milestone that had eluded the company for 75 years: the reacquisition of Bayer's trademark rights in the United States, restoring the brand to its original owner, and the listing of Bayer shares on the New York Stock Exchange.
Each of these leaders managed incremental evolution. The radical transformation would come next.
The Decade of Reinvention
The twenty-first century arrived with a strategic question that Bayer's management could no longer defer: What kind of company was this, actually? The portfolio had become a sprawl — chemicals, polymers, agricultural products, healthcare, diagnostics, specialty materials. The conglomerate discount was real and widening. Peer companies were specializing. The market was demanding clarity.
Werner Wenning, who became Chairman of the Board in 2002, began the restructuring in earnest. The company was reorganized into a strategic management holding with legally independent subgroups: Bayer HealthCare, Bayer CropScience, Bayer MaterialScience, and Bayer Chemicals. Each had its own board, its own P&L, its own strategic latitude. Then came the series of moves that would define Bayer's modern shape.
🔄
The Decade of Portfolio Surgery
Bayer's transformation from diversified conglomerate to focused life sciences company
2001Acquires Aventis CropScience for €7.25 billion, becoming a global leader in crop protection.
2005Acquires Roche consumer health business, becoming top-three in OTC medicines. Spins off chemicals and parts of polymers business as Lanxess AG.
2006Launches €17 billion takeover of Schering AG, acquiring 92.4% of shares by July. Enters oncology and women's healthcare at scale.
2007Sells Diagnostics
Division to Siemens for €4.2 billion.
2014Acquires Merck & Co. consumer care business and Norwegian oncology firm Algeta.
2015Covestro (formerly Bayer MaterialScience) IPOs on October 6, separating the last major non-life-sciences business.
2018
The logic was cumulative: shed chemicals, shed materials science, shed diagnostics — anything that didn't serve the life sciences mission — and double down on pharmaceuticals, consumer health, and crop science. Marijn Dekkers, who served as CEO from 2010 to 2016, completed the alignment with the Covestro IPO in 2015. By the time Werner Baumann succeeded him in May 2016, Bayer was a pure-play life sciences company with three divisions. Baumann had been a member of the Board since 2010 and most recently responsible for Strategy and Portfolio Management. He had been architecting the portfolio logic for years. The Monsanto acquisition was, from his perspective, the capstone — the deal that would close the last gap, combining Bayer's chemical crop protection expertise with Monsanto's unmatched seed genetics and digital agriculture platform.
Baumann would spend the rest of his tenure — seven years — defending that thesis against mounting evidence that the financial terms had been catastrophic.
The Anatomy of a Deal Gone Wrong
The Monsanto acquisition fails not because the strategic thesis was incoherent — it wasn't — but because the price paid rendered the thesis nearly irrelevant. At $128 per share in cash, Bayer paid a 44% premium to Monsanto's undisturbed price. The total enterprise value, including assumed debt and required divestitures, pushed the effective cost well beyond $63 billion. To finance it, Bayer issued roughly €19 billion in equity and took on massive debt. The balance sheet that emerged was fragile: net debt approaching the company's annual sales.
The litigation exposure was foreseeable but underestimated. Monsanto had been battling Roundup lawsuits for years before the acquisition. The International Agency for Research on Cancer (IARC), a branch of the World Health Organization, had classified glyphosate as "probably carcinogenic to humans" in 2015 — a year before Bayer even announced the deal. Government regulatory agencies in many countries continued to maintain that glyphosate was safe when used as directed, and Bayer would lean heavily on this regulatory consensus. But the legal system operates on different standards than regulatory science, and American juries proved receptive to plaintiffs' arguments.
The 2018 Johnson verdict — $289 million, later reduced — was the first domino. Two more trial losses followed. By June 2020, Bayer agreed to pay more than $10 billion to settle approximately 125,000 existing Roundup claims, with an additional $1.25 billion set aside for future litigation. The settlement also included up to $400 million for claims related to the herbicide dicamba and approximately $820 million for claims that Monsanto had polluted public waters with PCBs. The total financial exposure from the Monsanto inheritance exceeded $15 billion before accounting for ongoing legal costs and future claims.
This resolution will return the conversation about the safety and utility of glyphosate-based herbicides to the scientific and regulatory arena and to the full body of science.
It did not. New lawsuits continued to be filed. The stock continued to decline. Baumann's tenure became defined by the deal he had championed — a legacy of strategic ambition colliding with financial reality and legal entropy. He retired in May 2023 after 35 years of service, leaving behind a company that was, in the words of his successor, "badly broken in four places."
The Texan Who Arrived at the Worst Possible Moment
Bill Anderson is not what you expect when you hear "CEO of a 161-year-old German industrial company." A Texan by origin, he spent his career in the pharmaceutical industry — rising through the ranks at Roche, serving as CEO of Genentech, and then heading Roche's Pharmaceuticals division. He is the kind of executive who describes his management philosophy by referencing skateboarding injuries and speaks at conferences with the casual intensity of a startup founder. When Bayer's Supervisory Board Chairman, Norbert Winkeljohann, announced Anderson's appointment, he called him "the ideal candidate to lead Bayer together with the team into a new, successful chapter." Anderson took over on June 1, 2023.
He inherited a quadruple crisis. First, the Monsanto litigation: still unresolved, still generating new claims, still weighing on the share price like a concrete slab. Second, the balance sheet: €34.5 billion in net debt, close to the company's annual sales, with credit rating agency Fitch downgrading Bayer to BBB in March 2024. Third, the patent cliff: Xarelto, Bayer's bestselling drug — a blood-clot medication generating billions in annual revenue — faced patent exclusivity expiration in 2026, opening the market to generic competitors. Fourth, the organization itself: 12 levels of hierarchy, an internal rule book spanning 1,362 pages, a culture that Anderson diagnosed as structurally incapable of moving at the speed the business required.
Anderson compared the company's condition to fracturing his leg skateboarding: multiple breaks, each requiring attention, no single fix sufficient. His diagnosis was blunt and public. "Bureaucracy has put Bayer in a stranglehold," he wrote in a Fortune op-ed in the spring of 2024. The remedy he proposed was not incremental. It was, by the standards of a company this size, borderline revolutionary.
Dynamic Shared Ownership — or, What Happens When You Fire 5,000 Managers
In September 2023, three months after taking office, Anderson began implementing what he called Dynamic Shared Ownership, or DSO. The concept drew heavily on the ideas of management theorist Gary Hamel, whose book
Humanocracy argues for replacing hierarchical bureaucracy with networks of entrepreneurial micro-enterprises. Anderson cited the Chinese appliance manufacturer Haier — which had famously reorganized into thousands of self-managing microenterprises — as a precedent. But applying this model to a 160-year-old, 100,000-person German life sciences company operating under the codetermination system (in which the Supervisory Board is split equally between 10 shareholder representatives and 10 worker representatives) was an experiment without close analogue.
The mechanics: Annual budgets were eliminated. Org charts were discarded. The company's 1,362 pages of internal rules were to be replaced with judgment. Employees were organized into thousands of "mission teams" — project-based units of roughly 15 people, each functioning as a mini-startup with a "mission lead" who recruits members from across the company to pursue a specific goal over a series of 90-day sprints. At the end of each sprint, teams hold retrospectives. Based on feedback, 10–15% of employees rotate to new squads. Annual performance reviews were replaced by regular peer feedback. Budgets are reassessed and reallocated every 90 days.
If workers are hobbled by 1,000 rules, does it make a meaningful difference to reduce the rules to only 900? This is why most efforts fail — and why lasting progress requires eliminating all of the rules and then starting fresh with a new approach.
The result: approximately 5,500 layoffs, overwhelmingly concentrated in managerial positions, reducing the workforce to roughly 94,000. By late 2024, Bayer had targeted €2 billion in cost reductions by 2026, with a total of 12,000 job cuts anticipated. Anderson told Business Insider that voluntary attrition had actually declined — a data point he interpreted as evidence that employees valued the new autonomy.
The early results are genuinely mixed. Anderson cited drug development teams that had radically compressed timelines to human trials, scientists who had decreased plant breeding cycles from five years to four months, and a pharma division outside Milan that cut release times by 50% in Q3 2024. Skeptics note that Wall Street has remained unconvinced: Bayer's stock was cut roughly in half during Anderson's first year. The question of whether DSO is visionary organizational design or an elaborate euphemism for cost-cutting layoffs remains open. Both things can be simultaneously true.
Every large company has an organization problem. Bayer has some special attributes that make it even more challenging. One is that there's a little bit of fondness for rules that comes with the German culture that doesn't really play in the 21st century.
The Three Machines
Strip away the history, the litigation, and the organizational upheaval, and Bayer in its current form is three businesses stitched together under a life sciences thesis.
Pharmaceuticals is the prestige engine — the division that develops prescription drugs for cardiovascular disease, oncology, ophthalmology, and women's health. Xarelto (rivaroxaban), the anticoagulant, has been the division's commercial anchor. Eylea (aflibercept), for wet age-related macular degeneration, is the growth story. The pipeline includes cell and gene therapy candidates launched through Bayer's "leaps" initiative, established in November 2017 to pursue breakthrough innovations that complement traditional R&D. The division invests heavily — a substantial portion of Bayer's €6.2 billion annual R&D spend flows here — but faces the pharmaceutical industry's eternal challenge: the patent cliff is a ticking clock, and replacement therapies must be commercially ready before existing blockbusters lose exclusivity.
Consumer Health sells over-the-counter products under legacy brands that are, in some cases, more than a century old. Aspirin. Aleve. Claritin. Canesten. Bepanthen. This is the steady-state cash generator — lower growth, higher predictability, brand equity that compounds over decades. Bayer became a top-three global OTC supplier through the 2005 acquisition of Roche's consumer health business and the 2014 acquisition of Merck & Co.'s consumer care division.
Crop Science is the division that Monsanto built — and the one that carries most of the risk. It combines Bayer's legacy chemical crop protection business with Monsanto's seed and traits platform, the digital agriculture platform Climate FieldView, and the full portfolio of glyphosate-based herbicides. This is the division that generates the Roundup litigation. It is also the division that controls one of the world's most important seed genetics libraries and serves as Bayer's primary exposure to the structural challenge of feeding a growing global population.
Together, these three divisions produced €46.6 billion in sales in FY 2024, with €10.1 billion in EBITDA — a 13.5% decline year-over-year. The company employed roughly 94,000 people across more than 80 countries, invested €6.2 billion in R&D, and operated under a debt load that severely constrained its strategic flexibility. The question animating every decision at Bayer in 2025 is whether the three-division structure — the life sciences thesis that two decades of portfolio surgery was designed to create — still makes sense, or whether the company should be broken apart.
The Brand That Outlives Everything
The Bayer Cross — the company name written horizontally and vertically, intersecting at the shared letter "y" — was first conceived around 1900. Two origin stories survive in the corporate archives, and the company acknowledges both without resolving the discrepancy: one credits Hans Schneider of the Scientific Department in Elberfeld, who reportedly sketched it on a notepad during a conversation; the other credits a Dr. Schweizer in Bayer's New York office, who needed a more compact identifier than the company's unwieldy full name. Whoever designed it, the logo was registered on January 6, 1904, and replaced the company's original lion-and-grid heraldic emblem.
The cross has survived every institutional catastrophe the company has endured — absorption into I.G. Farben (where it was retained as the pharmaceutical sales trademark), dissolution by the Allies, postwar reconstitution, the loss and recovery of U.S. trademark rights, and the Monsanto debacle. It glows at the Leverkusen headquarters at night, a landmark visible for miles — switched off briefly each spring and fall so migratory birds don't become disoriented. It is stamped on every aspirin tablet, every box of Claritin, every bag of Crop Science seed. One of the world's most recognized corporate symbols, it carries a weight of association — trust, science, German engineering precision — that is, in some sense, the company's most durable asset. The disconnect between the brand's connotation and the company's actual condition — leveraged, litigious, organizationally turbulent — is the gap Bill Anderson is trying to close.
Bayer 04 Leverkusen, the Bundesliga football club, was founded in 1904 as a multi-sports organization for employees of the Bayer pharmaceutical company. Unlike nearly every other major German football club, it is a wholly owned subsidiary of Bayer AG — one of only two teams (alongside Volkswagen-owned Wolfsburg) to hold an exemption from the Bundesliga's 50+1 rule, which requires that a club's majority shareholding remain with its members. The city of Leverkusen itself was essentially built to serve the company: Bayer purchased the site in 1891, moved its headquarters there in 1912, and the urban fabric grew around the factory.
For decades, Leverkusen was known as Vizekusen — eternal runners-up, the team that finished second. In 2024, under head coach Xabi Alonso, they won the Bundesliga title unbeaten, completed a domestic double, and reached the Europa League final. The sporting triumph was a rare point of unqualified good news for a company desperately in need of one. It also served as an inadvertent proof of concept for the kind of organizational transformation Anderson was attempting: Alonso's Leverkusen was characterized by tactical flexibility, high pressing intensity, and a willingness to trust young players with autonomy — a footballing metaphor for DSO, if you squinted.
The club's success, however, could not arrest the parent company's stock decline. The market prices pharmaceutical liabilities and patent cliffs, not Bundesliga titles. The BayArena, modernized and expanded to over 30,000 capacity, sits adjacent to Bayer's Leverkusen campus — corporate headquarters and football stadium sharing a parking lot, the intimate geometry of a company town where institutional identity and sporting identity are literally the same thing.
What Science Owes and What It Costs
The Bayer archive contains 80,000 files comprising 28 million documents, 360,000 photographs, 6,000 film titles, and 20,000 exhibits. It is the institutional memory of a company that has contributed, in various registers, to human welfare and human suffering on scales that few private enterprises can match. Aspirin relieved the headaches of billions. Prontosil, discovered by Bayer scientist Gerhard Domagk — who won the 1939 Nobel Prize for Medicine for his work on the antibacterial effects of sulfonamides — inaugurated the age of antibiotics. Otto Bayer (no relation to the founding family), who joined the Leverkusen laboratory in 1933 at the age of 32, invented polyurethane chemistry — a family of plastics that would eventually touch every industry from construction to automotive to furniture. These are not incremental contributions. They are civilizational.
And then the other column. Heroin marketed to children. I.G. Farben and the Holocaust. The contaminated blood scandal — Cutter Laboratories, owned by Bayer since 1974, was one of the firms that manufactured Factor VIII, the blood-clotting protein used to treat hemophilia, which infected thousands with HIV and hepatitis in the 1970s and 1980s. Roundup and the unresolved question of glyphosate carcinogenicity. The neonicotinoid controversy and the documented impact on bee populations. Each episode reflects the same structural tension: a company whose scientific capabilities generate enormous value and whose institutional governance repeatedly fails to contain the risks those capabilities create.
Bill Anderson, the serial pharmaceutical CEO who insists on describing organizational bureaucracy as the root cause of Bayer's dysfunction, may be right that flatter structures and faster decision cycles can improve drug development timelines and crop science innovation. But the company's deepest historical failures were not caused by bureaucracy. They were caused by the subordination of ethics to institutional imperatives — by leaders who knew the risks and chose the returns. No operating model, however dynamic, solves for that.
In April 2023, shortly before Baumann's departure, Bayer established the Hans and Berthold Finkelstein Foundation, named for two young forced laborers at I.G. Farben's Lower Rhine sites. Its mission: to strengthen resistance against intolerance, totalitarianism, and hatred. The foundation supports independent research on the unjust regime during the Nazi era — an acknowledgment that the culture of remembrance must be actively maintained rather than passively inherited.
The Bayer Cross glows over Leverkusen. Inside the building beneath it, mission teams organize into 90-day sprints, reallocating budgets, rating each other's performance, racing to compress drug development cycles and breeding timelines. The archive — 28 million documents, 360,000 photographs — sits somewhere in the complex, a record of everything the company has been, everything it has done, everything it would prefer to do differently. The weight of it all is in the price: €20 billion for a company with €46.6 billion in revenue, €6.2 billion in annual R&D investment, and 161 years of compounding institutional knowledge. The market has decided that the liabilities outweigh the assets. Bill Anderson's wager is that the market is wrong — that beneath the debt, the litigation, and the 1,362 pages of rules, there is a company worth liberating.
The 90-day clock is ticking.
